The uveitis market was valued at USD 700.34 Million in 2024 driven by the increasing prevalence of the autoimmune disease among the 8 major markets. It is expected to grow at a CAGR of 6.00% during the forecast period of 2025-2034 and attain a market value of USD 1254.20 Million by 2034.
Base Year
Historical Year
Forecast Year
The market value is experiencing a rise in research investments as biotechnology companies are investigating new treatments and diagnostic tools to enhance patient outcomes, accelerating market growth.
In April 2024, Priovant Therapeutics announced favorable Phase 2 findings for brepocitinib in the treatment of non-anterior non-infectious uveitis, highlighting the growing importance of targeted treatments.
The United States is expected to lead the market share on the basis of region due to the increasing prevalence of autoimmune diseases, which contribute to the rise of uveitis.
Uveitis is an inflammatory condition affecting the uvea of the eye, causing pain, redness, and sometimes blindness. The market for uveitis treatment includes anti-inflammatory, immunosuppressive, and biologic therapies aimed at controlling inflammation and preventing long-term damage. The market growth is expected to be driven by the rise in autoimmune diseases and the emphasis associated with early diagnosis of the condition.
Rising Prevalence of Autoimmune Diseases Drives Market Growth
The rise in autoimmune diseases, such as rheumatoid arthritis and lupus, which are associated with secondary uveitis. These conditions often exacerbate ocular inflammation, thus, driving demand for uveitis treatments. According to the National Health Council, around 50 million Americans are affected by autoimmune diseases, with some research suggesting an annual rise of 3-12%, indicating that autoimmunity is becoming more prevalent. This growing challenge highlights the immediate need for innovative treatments and targeted solutions.
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Treatment Holds a Significant Market Share
Based on the treatment, the market is segmented into anti-inflammatory, immunosuppressive, antibiotics, and others. Among these, anti-inflammatory treatments are expected to lead the market because of their central role in managing the condition. Uveitis is predominantly characterized by inflammation, making anti-inflammatory treatments like corticosteroids and biologics the first choice for treatment. These treatments effectively reduce eye inflammation and protect against long-term damage.
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share in the forecast period due to a favorable regulatory environment that will result in more drug approvals. Furthermore, the market receives a significant boost from the presence of major healthcare and pharmaceutical companies in the region.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
AbbVie, based in North Chicago, USA, specializes in developing treatments for immunology and ophthalmology. Their product portfolio includes Humira (adalimumab), a biologic that suppresses the immune system and is utilized to treat autoimmune uveitis by decreasing inflammation.
Headquartered in Laval, Canada, Bausch Health provides a range of products designed for maintaining eye health. Bausch Health Companies acquired the rights to use XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) from Clearside Biomedical for the treatment of macular edema linked to uveitis.
Based in Basel, Switzerland, Novartis holds a significant presence in the field of ophthalmology. The range of treatments they offer for uveitis includes Ilaris (canakinumab), a medication that inhibits interleukin-1 beta to address inflammation in the eye condition.
Roche, based in Basel, Switzerland, offers biologics such as Actemra (tocilizumab), an IL-6 inhibitor used off-label for uveitis treatment. Roche is dedicated to progressing its ophthalmic pipeline, which includes treatments for inflammatory eye conditions such as uveitis.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include EyePoint Pharmaceuticals, Inc., Alimera Sciences, Inc., Aldeyra Therapeutics, Inc., Lux Biosciences, Inc., Amgen Inc., and Santen Pharmaceutical Co., Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share